Jeffrey Leathe was most recently the Chief Executive Officer and Chairman of the Board at Biocius Life Sciences, a venture backed company involved in developing high throughput instrumentation for mass spectrometry applications in pharmaceutical drug discovery and clinical diagnostic testing. Biocius was acquired by Agilent Technologies in February 2011. Prior to Biocius, Mr. Leathe served as the Senior Vice President and Chief Financial Officer of BioTrove Inc., a venture backed company developing a high throughput PCR platform for use in drug discovery and development. Mr. Leathe was the chief architect of the sale of BioTrove to LIFE Technologies in December 2009.
Before joining BioTrove, Mr. Leathe served as Executive Vice President, Chief Financial Officer and Treasurer for Apogent Technologies from 1990-2003. Apogent, a formerly NYSE-listed global manufacturer of life science research and clinical diagnostic instruments and consumables, was subsequently sold to Fisher Scientific. At Apogent, Jeff managed numerous life science companies around the globe and was a key driver of acquisitions and related public equity and debt financings in excess of $3 billion in the life sciences space.
Jeff is a director and chairman of the audit committee for Bottomline Technologies, a NASDAQ-listed software firm. Jeff received his MBA from the University of North Carolina, Chapel Hill, his B.S. from the University of New Hampshire and holds his CPA.
Gregory C. Critchfield, MD, MS
Dr. Critchfield is the Chairman and CEO of Sera Prognostics Inc., a women’s healthcare company, which recently announced a program for early limited commercial access to PreTRM™, a proteomic biomarker blood test designed to provide an early, objective, and individualized assessment of a woman’s risk of preterm birth. Before joining Sera, Dr. Critchfield was President of Myriad Genetics Laboratories from 1998-2010. Under his leadership, Myriad launched seven novel molecular diagnostic products across a variety of technology platforms and increased annual revenues from $2.2 million to $326.5 million. Prior to Myriad, he served as Senior Vice President and Chief Medical and Science Officer at Corning Clinical Laboratories/Quest Diagnostics. In addition to Lantos Technologies, Dr. Critchfield also serves on the boards of Integrated Diagnostics, Nodality, and Metamark Genetics. He holds a B.S. in Microbiology from BYU, an M.D. from the University of Utah College of Medicine, and an M.S. in Biophysical Sciences from the University of Minnesota.
Peter Kolchinsky, PhD
Peter Kolchinsky is a founder, Managing Director and Portfolio Manager at RA Capital Management, a crossover fund manager dedicated to evidence-based investing in healthcare and life science companies. He is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools, and serves as a member of the Board of Directors of Dicerna Pharmaceutics and a number of private companies. Peter also leads the firm’s outreach and publishing efforts, which aim to make a positive social impact and spark collaboration among healthcare stakeholders, including patients, physicians, researchers, policy makers and industry. He authored “The Entrepreneur’s Guide to a Biotech Startup” and served on the Board of Global Science and Technology for the National Academies of Sciences. Peter received a Bachelor’s degree from Cornell University and a PhD in Virology from Harvard University.
Andrew G. Raguskus
Andy has over 40 years of experience in delivering high tech products to market, 18 of them in the hearing device industry. He was the Senior Vice President of Operations at ReSound Corporation in the 1990’s and served Sonic Innovations as President and CEO from 1996 to 2005, where he led the company to become one of the medical device industry’s entrepreneurial success stories.
Mr. Raguskus was named “Utah Entrepreneur of the Year” in 2001 by Ernst & Young, CNN, USA Today, and NASDAQ. He began his career designing satellites as a U.S. Air Force officer and was part of the design team for the original CT scanner at General Electric Medical Systems. Currently, Mr. Raguskus is also the CEO of OtoKinetics Inc. a venture backed startup that is developing a fully implantable hearing device similar to a cochlear implant. Mr. Raguskus earned a Bachelor’s Degree in Electrical Engineering from Rensselaer Polytechnic Institute.
Darshana is a Partner at Catalyst Health Ventures, a Healthcare focused venture capital firm. She is a member of Catalyst’s investment committee and actively involved in all aspects of Fund Management including deal origination, management and capital raising. She led Catalyst’’s investments in Augmenix, Lantos Technologies, nVision Medical, Hepregen and Maxwell Health.
Prior to Catalyst, she was an Investigator at Vertex Pharmaceuticals and an integral part of the drug development programs in oncology, metabolic disease, and immunology. Previously she worked at Genome Therapeutics, a Massachusetts-based biotechnology company, at the Dana Farber Cancer Institute and completed an internship at the United Nations. She has authored several publications and scientific journal articles and currently serves as a Catalyst of the Deshpande Center for Technological Innovation at MIT.
Darshana received an MPA from Harvard University, a Master in Cell and Molecular Biology from Boston University, and a BS in Biochemistry from Bombay University in Bombay, India.